AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio

Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal

Novartis Spinoff Sandoz to Start Trading as Standalone Drugmaker

China Drug-Price Negotiations Offers Glimpse Into Future for Companies in US

AbbVie trims full-year profit forecast on higher R&D expenses

Roivant Attracts Interest for $7 Billion-Plus Bowel Drug

Zuckerberg Is Helping to Propel Chicago’s Biotech Ambitions

Astra Drops Bowel Disease Drug Program After Delays

US FDA approves Genmab-AbbVie's blood cancer therapy

Teva Plans to Cut Back Generic Drug Production Even As Shortages Intensify

Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data

Pfizer Sells $31 Billion of Bonds in Fourth-Largest Deal Ever